GSK India aims to double revenue to ₹8,000 crore by FY30, with oncology and adult vaccines emerging as key growth drivers alongside its general-medicines portfolio
Popular Posts
-
India is betting on Semicon 2.0 and a China+1 strategy to build a competitive semiconductor ecosystem, targeting mature-node chips and a lar...
-
The department is sharing knowledge and supporting technology development as India seeks greater private-sector participation in nuclear man...
